Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine (Nasdaq: CMND) announced the first participant was enrolled and dosed with CMND-100 at Hadassah-University Medical Center in Jerusalem on Dec. 2, 2025 as part of its multinational Phase I/IIa trial for Alcohol Use Disorder (AUD).

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) announced the first participant was enrolled and dosed with CMND-100 at Hadassah-University Medical Center in Jerusalem on Dec. 2, 2025 as part of its multinational Phase I/IIa trial for Alcohol Use Disorder (AUD).

The trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s MEAI-based oral candidate. Recent top-line results from the first cohort were described as positive and the Data and Safety Monitoring Board gave a unanimous recommendation to continue, supporting trial momentum across active sites.

Positive

• First participant dosed with CMND-100 at Hadassah on Dec. 2, 2025
• Multinational Phase I/IIa trial expanding to Hadassah site
• Unanimous DSMB recommendation to continue the clinical trial
• Positive top-line results reported from the trial’s first cohort

Argus Dec 2 session

-9.94% close to close Open Argus

Details

News Market Reaction – CMND

On Dec 2, the day this news came out, CMND closed 9.94% below the previous close.

Data tracked by StockTitan Argus for the Dec 2 session.

Market Context

On Dec 2, the day this news came out, the stock closed 9.9% below the previous close. A negative rea...

Analysis

On Dec 2, the day this news came out, the stock closed 9.9% below the previous close. A negative reaction despite a positive clinical milestone fits recent patterns, where favorable CMND-100 updates were followed by declines such as -21.85%, -19.4%, and -6.92%. Investors had also been digesting multiple financings and Nasdaq compliance challenges, which can weigh on sentiment even as the Phase I/IIa trial advances. Such context suggests that broader balance-sheet and listing concerns have often overshadowed incremental clinical progress.

Historical Context

5 past events · Latest: Dec 10

5 events

1. Dec 10

   Reverse share split

   24h Move

   -6.1%

   1-for-40 reverse split to address Nasdaq minimum bid price compliance.

2. Dec 05

   Nasdaq notice

   24h Move

   +2.5%

   Nasdaq minimum bid price noncompliance notice with 180-day cure period.

3. Dec 02

   Clinical trial update

   24h Move

   -9.9%

   First participant dosed with CMND-100 at Hadassah in Phase I/IIa AUD trial.

4. Dec 01

   Clinical milestones

   24h Move

   -6.9%

   Positive cohort data, DSMB continuation, and new elite trial site added.

5. Nov 25

   Site enrollment

   24h Move

   -19.4%

   First patient enrolled at Tel Aviv Sourasky Medical Center in Phase I/IIa trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

alcohol use disorder, phase i/iia, pharmacokinetics, data and safety monitoring board

4 terms

alcohol use disorder medical

"clinical trial for the treatment of Alcohol Use Disorder (AUD): the first participant"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

phase i/iia medical

"another key milestone in its Phase I/IIa clinical trial for the treatment"

An early-stage clinical trial program that combines Phase I (primarily testing safety and finding a tolerable dose) with Phase IIa (initial checks for whether the drug shows signs of working in patients). Think of it as trying a new product with a small group to confirm it’s safe and gives early benefits before a larger rollout. For investors, these studies are major risk/reward checkpoints: positive results can boost value, while failures are common and costly.

pharmacokinetics medical

"trial evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

data and safety monitoring board medical

"and unanimous Data and Safety Monitoring Board recommendation that the clinical trial"

An independent panel of experts that watches over a clinical trial to protect participants and ensure the data are reliable, acting like an impartial referee who can recommend pausing or stopping the study if safety problems or clear benefits emerge. Investors care because the board’s findings can change a drug or device’s timeline, cost, and odds of regulatory approval, directly affecting a company’s value and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD): the first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah-University Medical Center in Jerusalem, Israel.

The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco, Director of the Clinical Pharmacology Unit in the Department of Medicine. This site is part of the Company’s multinational Phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with AUD. Recent positive top-line results from the first cohort and unanimous Data and Safety Monitoring Board recommendation that the clinical trial continue contribute to supporting strong momentum across all active sites.

“We believe that dosing the first participant with CMND-100 at Hadassah Medical Center marks yet another significant step forward in expanding our global trial footprint and accelerating our path to potentially delivering innovative treatments for AUD,” said Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind Medicine. “Hadassah’s expertise in clinical research, combined with our encouraging early data from the first cohort, brings us closer to potentially transforming the lives of millions affected by alcohol use disorder.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the strong momentum across all of its active clinical sites, its belief that dosing the first participant with CMND-100 at Hadassah Medical Center marks another significant step forward in expanding its global trial footprint and accelerating its path to potentially delivering innovative treatments for AUD and potentially transforming the lives of millions affected by alcohol use disorder . Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind (CMND) announce on Dec. 2, 2025 about CMND-100?

Clearmind announced the first participant was enrolled and dosed with CMND-100 at Hadassah-University Medical Center in Jerusalem as part of its Phase I/IIa AUD trial.

What is the purpose of the Phase I/IIa CMND-100 trial (CMND)?

The trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with alcohol use disorder.

What recent data update did Clearmind (CMND) report about the trial?

Clearmind reported positive top-line results from the first cohort and a unanimous Data and Safety Monitoring Board recommendation to continue the trial.

Who is leading the Hadassah site for Clearmind’s CMND-100 trial?

The Hadassah-University Medical Center site is led by Prof. Joseph Caraco, Director of the Clinical Pharmacology Unit.

How does the Hadassah dosing affect Clearmind’s CMND (Nasdaq: CMND) development plans?

Dosing the first participant at Hadassah expands the trial’s global footprint and supports continued enrollment across active sites per the company.